ClinicalTrials.gov
public full text
Public Domain
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients#208413
- Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients#405114
- Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)#994547
- Vemurafenib and White Blood Cell Therapy for Advanced Melanoma#668830
- PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma#1096250
Record · ID 898097
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive